

# Succinic Acid Monoethyl Ester and Metformin Regulates Carbohydrate Metabolic Enzymes and Improves Glycemic Control in Streptozotocin-Nicotinamide Induced Type 2 Diabetic Rats

LEELAVINOTHAN PARI and RAMALINGAM SARAVANAN

Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu, India.

Received September 9, 2005; Revised February 28, 2006; Accepted February 29, 2006

This paper is available online at <http://ijpt.iuims.ac.ir>

## ABSTRACT

**Objective.** Succinic acid mono ethyl ester (EMS) was recently proposed as an insulinotropic agent for the treatment of non-insulin dependent diabetes mellitus. In the present study the effect of EMS and Metformin on the activities of carbohydrate metabolic enzymes in streptozotocin–nicotinamide induced type 2 diabetic model was investigated. **Methods.** EMS were injected intraperitoneally at doses 2, 4, and 8  $\mu\text{mol/g}$  body weight (bw) respectively for 30 days, after which blood hemoglobin, glycosylated hemoglobin, plasma glucose and insulin, hexokinase, glucose-6-phosphatase, fructose-1, 6-bisphosphatase, glucose-6-phosphate dehydrogenase in liver and glycogen in liver and muscle were assayed. **Results.** Glucose, glycosylated hemoglobin, glucose-6-phosphatase and fructose-1,6-bis phosphatase were significantly increased and insulin, hemoglobin, hexokinase, glucose-6-phosphate dehydrogenase and glycogen were significantly decreased in diabetic rats. The enzyme activities were restored to the near normal levels in diabetic rats treated with EMS and Metformin. **Conclusion.** Our result suggest that non glucidic nutrient- EMS may act as a potent antidiabetic and insulinotropic agent by restoring the above biochemical alterations in streptozotocin -nicotinamide induced type 2 diabetes.

**Keywords:** Succinic Acid Monoethyl Ester, Nicotinamide, Metformin, Carbohydrate enzymes, Diabetes mellitus

Type 2 diabetes is a chronic metabolic disorder characterized by abnormalities in carbohydrate and lipid metabolism [1]. It represents a heterogeneous group of disorders having hyperglycemia, which is due to impaired carbohydrates (glucose) utilization resulting from a defective or deficient insulin secretory response. The liver plays a pivotal role in glucose and lipid homeostasis [2]. In experimental diabetes, enzymes of glucose metabolism are markedly altered and produce hyperglycemia, which leads to pathogenesis of diabetic complications [3]. Glucose homeostasis involves the coordinated regulation of several metabolic pathways including gluconeogenesis and glycolysis.

A number of therapeutic tools for the treatment of non-insulin dependent diabetes mellitus are currently available. A wide variety of structurally distinct molecules stimulate insulin secretion from pancreatic  $\beta$  cells by different mechanism of action. The ester carboxylic nutrient succinic acid (mono ethyl ester) derivative is a low toxicity drug (Fig 1) [5] and has attracted consider-




Fig 1. Structure of succinic acid monoethyl ester.

able interest for more than a decade as possible therapeutic agent for the treatment of type 2 diabetes. This is based on the ability of EMS to act as potent stimulator of insulin secretion. It has previously been shown that succinic acid ester can be taken up and metabolized by pancreatic  $\beta$  cells, leading to increased pro-insulin biosynthesis [6], insulin secretion and lower the blood glucose [7, 8]. Its ester also protects pancreatic islets *in vivo* and *in vitro* against diabetogenic agents streptozotocin [9], interleukin  $1\beta$  [10], and nitric oxide donor (NO) [11]. EMS is a suitable nutrient both to cover the energy need of hepatocytes and act as a gluconeogenic precursors [12].

**Table 1.** Effect of EMS on body weight and food intake in control and experimental rats.

Groups	Changes in body weight (g)		Food intake (g/rat per day)	
	Initial	Final	Before	After
Control	186.5±15.8	195.6±16.6 <sup>ns</sup>	14.3±1.2 <sup>**</sup>	15.06±1.03 <sup>ns</sup>
Normal + EMS (8 µmol/g)	185.9±13.51	191.0±13.8 <sup>**</sup>	17.4±1.1 <sup>***</sup>	16.43±0.9 <sup>***</sup>
Diabetic Control	182.4±10.0	160.3±9.6 <sup>ns</sup>	41.7±2.5 <sup>**</sup>	56.67±3.4 <sup>**</sup>
Diabetic + EMS (2 µmol/g)	183.2±10.97	166.3±10.0 <sup>ns</sup>	35.5±2.0 <sup>**</sup>	48.40±2.8 <sup>***</sup>
Diabetic + EMS (4 µmol/g)	184.2±11.0	168.3±10.0 <sup>**</sup>	32.5±2.1 <sup>***</sup>	29.90±2.5 <sup>***</sup>
Diabetic + EMS (8 µmol/g)	185.2±11.1	192.3±11.5 <sup>**</sup>	24.9±2.1 <sup>***</sup>	40.18±2.6 <sup>***</sup>
Diabetic + Metformin (25mg/kg)	184.6±11.0	190.16±11.8 <sup>ns</sup>	23.8±2.0 <sup>ns</sup>	30.16±1.8 <sup>***</sup>

Values are given as mean ± SD from 6 rats in each group. Diabetic control was compared with normal. Experimental groups were compared with the diabetic control group.

\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , <sup>ns</sup> non significant.

Generally non-glucidic nutrients control hyperglycemia, resulting in improved overall glycemic control in patients with type 2 diabetes.

Metformin is an oral hypoglycemic agent, which belongs to the class known as the biguanides. Chemically it is N-N dimethylimidodicarbonimidic diamide [13]. Metformin is now widely used as one of the mainstays in the management of type 2 diabetes. Metformin reduces fasting plasma glucose concentration by reducing rate of hepatic glucose production via gluconeogenesis and glycogenolysis. Metformin improves glycemic control as monotherapy and in combination with other oral antidiabetic agents, such as sulfonylureas and thiazolidine diones [14].

To our knowledge there are no other available reports on the effect of nonglucidic nutrient EMS on enzymes of hepatic glucose metabolism in streptozotocin-nicotinamide induced type 2 diabetes. Therefore the aim of the present study was to explore the effect of EMS on key hepatic enzyme in diabetic rats. The effect of EMS was compared with conventional antidiabetic agent metformin.

## MATERIALS AND METHODS

### Drug and Chemicals

Succinic acid monoethyl ester, and all other biochemicals and chemicals used in this experiment were purchased from Sigma chemical company Inc., St Louis, MO, USA. The chemicals were of analytical grade.

### Animals

Healthy male albino Wistar strain rats (200-220g body weight) obtained from Central Animal House, Rajah Muthiah Medical College, Annamalai University

were used in the present study. The rats were fed on pellet diet (Hindustan Lever Limited, Mumbai, India) and water ad libitum. The rats used in the present study were maintained in accordance with the guidelines of the National Institute of Nutrition, Indian Council of Medical Research, Hyderabad, India and the study approved by the ethical committee (Vide. No:285,2005), Annamalai University.

### Experimental Induction of Type 2 Diabetes in Rats

Non-Insulin dependent diabetes mellitus (NIDDM) was induced in overnight fasted rats by a single intraperitoneal injection of 45 mg/kg streptozotocin, 15 min after the i.p administration of 110 mg/kg body weight of nicotinamide. Streptozotocin (STZ) was dissolved in citrate buffer (pH 4.5) and nicotinamide was dissolved in normal saline. Hyperglycemia was confirmed by the elevated glucose levels in plasma, determined at 72 h and then on day 7 after injection. The rats found with permanent NIDDM were used for the study [15].

### Experimental Procedure

In the experiment, a total of 42 rats (36 diabetic surviving rats, 6 control rats). Were used the rats were divided into seven groups of six rats each.

- **Group I.** Control rats (salin treated).
- **Group II.** Normal rats administered intraperitoneally with EMS 8 µ mol/g bw for 30 days.
- **Group III.** Diabetic control rats.
- **Group IV.** Diabetic rats administered intraperitoneally with EMS 2 µ mol/g bw for 30 days.
- **Group V.** Diabetic rats administered intraperitoneally with EMS 4 µ mol/g bw for 30 days.
- **Group VI.** Diabetic rats administered intraperitoneally with EMS 8 µ mol/g bw for 30 days.

**Table 2.** Effect of EMS on changes in plasma glucose and insulin in Control and experimental rats.

Groups	Plasma glucose (mg/dl)	Plasma insulin (µU/mL)
Control	87.13±7.41 <sup>ns</sup>	10.51±0.89 <sup>ns</sup>
Normal + EMS (8 µmol/g)	80.77±5.87 <sup>***</sup>	11.31±0.82 <sup>***</sup>
Diabetic Control	262.28±15.71 <sup>***</sup>	5.20±0.31 <sup>***</sup>
Diabetic + EMS (2 µmol/g)	141.54±11.0 <sup>***</sup>	7.38±0.57 <sup>***</sup>
Diabetic + EMS (4 µmol/g)	113.47±8.86 <sup>***</sup>	8.07±0.63 <sup>***</sup>
Diabetic + EMS (8 µmol/g)	101.72±5.73 <sup>***</sup>	9.67±0.54 <sup>***</sup>
Diabetic + Metformin (25 mg/kg)	98.50±7.70 <sup>ns</sup>	8.96±0.50 <sup>ns</sup>

Values are given as mean ± SD from 6 rats in each group. Diabetic control was compared with normal. Experimental groups were compared with the diabetic control group.

\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , <sup>ns</sup> non significant.

**Table 3.** Effect of EMS on changes in the levels of hemoglobin, glycosylated hemoglobin and urine sugar in control and experimental rats.

Groups	Hemoglobin (g/dl)	Glycosylated hemoglobin (mg/g Hb)	Urine sugar
Control	11.60±0.68 <sup>ns</sup>	0.24±0.02 <sup>ns</sup>	Nil
Normal + EMS (8µmol/g)	12.77±0.87 <sup>***</sup>	0.23±0.01 <sup>***</sup>	Nil
Diabetic control	7.08±0.60 <sup>***</sup>	0.82±0.05 <sup>***</sup>	+++
Diabetic + EMS (8µmol/g)	10.90±0.59 <sup>*</sup>	0.35±0.02 <sup>***</sup>	Nil
Diabetic + Metformin (25 mg/kg)	9.98±0.44 <sup>*</sup>	0.40±0.03 <sup>*</sup>	Trace

Values are given as mean ± SD from 6 rats in each group. Diabetic control was compared with normal. Experimental groups were compared with the diabetic control group.

\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , <sup>ns</sup> non significant. +++ Indicates more than 2% sugar.

- **Group VII.** Diabetic rats given Metformin 25 mg/kg bw [16] in 1 mL of saline for 30 days.

At the end of experimental period, the rats were deprived of food overnight and blood was collected in a tube containing potassium oxalate and sodium fluoride for the estimation of blood glucose, hemoglobin and glycosylated hemoglobin. Plasma was separated for the assay of insulin. Liver was dissected out, washed in ice-cold saline, patted dry and weighed.

### Analytical Methods

#### Determination of Plasma Glucose and Insulin.

Plasma glucose was estimated calorimetrically using commercial diagnostic kits (Sigma Diagnostics (I) Pvt Ltd, Baroda, India) [17]. Plasma insulin was assayed using an enzyme linked immunosorbent assay (ELISA) kit (Boehringer–Mannheim, Germany). Hemoglobin was estimated by using the cyanmethemoglobin method described by Drabkin and Austin [18]. Glycosylated hemoglobin was estimated according to the method of Sudhakar Nayak and Pattabiraman [19] with modifications according to Bannon [20].

#### Determination of Liver Carbohydrate Enzymes.

Glucose-6-phosphatase and fructose-1, 6-bisphosphatase were assayed according to the method of Koida and Oda [21] and Gancedo and Gancedo [22] respectively and the inorganic phosphorus (Pi) liberated was estimated by the method of Fiske and Subbarow [23]. Hexokinase and glucose-6-phosphate dehydrogenase were determined by the method of Brandstrup et al [24] and Ellis and Kirkman [25] respectively.

#### Determination of Liver and Muscle Glycogen.

Liver and muscle glycogen was estimated by the method of Morales et al. [26].

**Statistical Analysis.** All the grouped data were statistically evaluated and the significance of various treatments was calculated using Student's *t*-test. All the results were expressed as mean ± S.D.

## RESULTS

**Table 4.** Effect of EMS on changes in the levels of liver and muscle glycogen in control and experimental rats.

Groups	Glycogen (mg/g tissue)	
	Liver	Muscle
Control	34.6 ± 2.4 <sup>ns</sup>	5.5 ± 0.4 <sup>ns</sup>
Normal + EMS (8µmol/g)	35.7 ± 2.1 <sup>***</sup>	5.6 ± 0.3 <sup>***</sup>
Diabetic control	23.4 ± 1.8 <sup>**</sup>	2.7 ± 0.2 <sup>***</sup>
Diabetic + EMS (8µmol/g)	29.5 ± 1.7 <sup>*</sup>	4.8 ± 0.3 <sup>***</sup>
Diabetic + Metformin (25 mg/kg)	26.8 ± 2.3 <sup>ns</sup>	4.0 ± 0.3 <sup>**</sup>

Values are given as mean ± SD from 6 rats in each group. Diabetic control was compared with normal. Experimental groups were compared with the diabetic control group.

\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , <sup>ns</sup> non significant.

### Body Weight and Food Intake

The changes in the body weight and food intake in control and experimental rats are represented in Table 1. The body weights in EMS and metformin treated diabetic rats increased significantly at the end of the experimental period when compared with diabetic control rats. Food intake significantly increased in diabetic rats and it was significantly reduced in EMS and metformin treated groups compared to diabetic control rats.

### Plasma Glucose and Insulin Levels

Table 2 demonstrates the level of plasma glucose and insulin in control and experimental animals. The level of plasma glucose was significantly increased whereas plasma insulin was significantly decreased in streptozotocin-nicotinamide diabetic rats. The administration of EMS significantly reversed the changes in a dose dependent manner. EMS at a dose of 8 µmol/g body weight showed a highly significant effect compared to 2 and 4 µmol/g body weight. Administration of EMS was compared with metformin, a reference drug. The effect of EMS at a dose 8 µmol/g body weights was used for further biochemical analysis.

### Hemoglobin and Glycosylated Hemoglobin Levels

Table 3 shows the level of hemoglobin and glycosylated hemoglobin of different experimental groups. The diabetic rats showed a significant decrease in the level of total hemoglobin and a significant increase in the level of glycosylated hemoglobin. The administration of EMS and metformin to diabetic rats reversed the changes in total hemoglobin and glycosylated hemoglobin.

### Liver and Muscle Glycogen Levels

Table 4 shows the changes in the level of liver and muscle glycogen of control and experimental rats. There was a significant reduction in liver and muscle glycogen of STZ-nicotinamide diabetic rats. Administration of EMS and metformin significantly increased the level of

liver and muscle glycogen.

### Hepatic Carbohydrate Enzymes Levels

Table 5 shows the changes in the activities of hepatic gluconeogenic enzymes (glucose-6-phosphatase and fructose 1, 6-bisphosphatase), hexokinase, and glucose-6-phosphate dehydrogenase in different experimental groups. The activities of hepatic gluconeogenic enzymes were significantly increased whereas hexokinase and glucose-6-phosphate dehydrogenase were significantly decreased in STZ-nicotinamide diabetic rats. Administration of EMS and metformin to diabetic rats reversed the changes in the activities of these hepatic enzymes to almost control levels.

## DISCUSSION

The ester of selected carboxylic metabolites, which are mediators in the Krebs cycle or their precursors such as pyruvic acid, succinic acid, and glutamic acid are currently under investigation as potent insulinotropic tools in the treatment of non insulin dependent diabetes [27]. The insulinotropic capacity of succinic acid monoethyl ester was first disclosed in pancreatic islets [28]. The nutritional value of this ester when infused to starved rats has been recently documented [29]. The fundamental mechanism underlying hyperglycemia in diabetes mellitus involves over-production (excessive hepatic glycogenolysis and gluconeogenesis) and decreased utilization of glucose by the tissues [30].

The administration of EMS and metformin to decrease the increased blood glucose concentration to normal glycemic concentration is an essential trigger for the liver to revert its normal homeostasis during experimental diabetes. Glucose is metabolized in the pancreatic  $\beta$  cell via glycolysis in the cytosol resulting in pyruvate production. Pyruvate is then transported into the mitochondria for Krebs cycle metabolism supporting subsequent oxidative phosphorylation and ATP production [31-33]. Generation of ATP by increased glucose metabolism promotes a rise in the cytosolic ATP/ADP ratio, closure of the ATP dependent  $K^+$  channel, opening of the voltage sensitivity  $Ca^{2+}$  channels and a subsequent increase in the cytosolic free calcium concentration resulting in triggering of proinsulin synthesis and

insulin release [6, 7] promoted by EMS. Metformin reduces fasting plasma glucose level by reducing rates of hepatic glucose production, [34, 35] its effect on the relative contributions of hepatic glycogenolysis [36, 37] and gluconeogenesis [38]. EMS treatment significantly decreases plasma glucose and increases plasma insulin level compared with metformin.

EMS at  $8\mu\text{mol/g}$  body weight was significantly better than 2 and  $4\mu\text{mol/g}$  body weight; therefore high dose was used further biochemical studies.

In uncontrolled or poorly controlled diabetes, there is an increased glycation of a number of proteins including hemoglobin and alpha-crystalline of lens [39]. Glycated hemoglobin has been found to be significantly increased in diabetic animals and this increase was directly proportional to fasting blood glucose [40]. Anemia is a much more common disease in type 2 diabetic patients, potentially contributing to the pathogenesis of diabetic complications. Hemoglobin was also recorded as a binary outcome for estimating the risks for anemia [41]. In the present study, the decreased level of hemoglobin indicates the anemia in STZ-nicotinamide diabetic rats. Since during diabetes, the excess glucose transport in the blood reacts with hemoglobin to form glycosylated hemoglobin. Administration of EMS with metformin controls the glycation of hemoglobin by its normoglycemic activity and thus decreases the level of glycated hemoglobin in STZ-nicotinamide diabetic rats.

In our study, hepatic and skeletal muscle glycogen content was reduced significantly in diabetic controls. Insulin is the main regulator of glycogenesis in muscle and liver. The decrease in hepatic and skeletal muscle glycogen contents in diabetic rats have been observed earlier by Pari and Latha [42]. The decrease in both muscle and hepatic glycogen observed in this study may be due to lack of insulin in the diabetic state and this type of results is probably due to the inactivation of glycogen synthetase system. EMS for 30 days in diabetic rats resulted in a significant elevation of liver and muscle glycogen levels. This shows the one possible way of antidiabetogenic action of this nonglucidic nutrient may be improvement of glycogenesis process in muscle and liver.

Hexokinase and glucose-6-phosphate dehydrogenase activities have been observed to decrease in STZ diabetic

**Table 5.** Effect of EMS on changes in the activities of hepatic hexokinase, glucose-6-phosphate dehydrogenase, glucose-6-phosphatase, and fructose-1, 6- bisphosphatase in control and experimental rats.

Groups	Control	Normal + EMS (8 $\mu\text{mol/g}$ )	Diabetic control	Diabetic + EMS (8 $\mu\text{mol/g}$ )	Diabetic + Metformin (25 mg/kg)
Hexokinase (units <sup>1</sup> /g protein)	145.27 $\pm$ 8.63 <sup>ns</sup>	152.91 $\pm$ 10.50 <sup>***</sup>	106.90 $\pm$ 6.79 <sup>**</sup>	132.02 $\pm$ 7.19 <sup>**</sup>	126.81 $\pm$ 5.60 <sup>ns</sup>
Glucose-6-phosphate dehydrogenase ( $\times 10^4$ mIU / mg protein)	4.54 $\pm$ 0.27 <sup>**</sup>	3.92 $\pm$ 0.27 <sup>***</sup>	2.01 $\pm$ 0.12 <sup>***</sup>	3.50 $\pm$ 0.19 <sup>***</sup>	2.89 $\pm$ 0.12 <sup>**</sup>
Glucose-6-phosphatase (units <sup>2</sup> /mg protein)	0.12 $\pm$ 0.01 <sup>ns</sup>	0.13 $\pm$ 0.01 <sup>***</sup>	0.26 $\pm$ 0.02 <sup>***</sup>	0.16 $\pm$ 0.01 <sup>**</sup>	0.17 $\pm$ 0.01 <sup>ns</sup>
Fructose-1,6-bisphosphatase (units <sup>3</sup> /mg protein)	0.29 $\pm$ 0.02 <sup>ns</sup>	0.26 $\pm$ 0.07 <sup>***</sup>	0.48 $\pm$ 0.03 <sup>***</sup>	0.36 $\pm$ 0.02 <sup>**</sup>	0.40 $\pm$ 0.03 <sup>ns</sup>

Values are given as mean  $\pm$  SD from 6 rats in each group. Diabetic control was compared with normal. Experimental groups were compared with the diabetic control group.

\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , <sup>ns</sup> non significant.

$\mu\text{moles}$  of glucose phosphorylated/min.

$\mu\text{moles}$  of Pi liberated/min.

$\mu\text{moles}$  of Pi liberated/hour

ic rats, which may be due to loss of insulin receptors [43], production of glycated proteins and formation of amadori product [44]. Hexokinase plays an important role in the maintenance of glucose homeostasis and all the cells that metabolize glucose by ATP to produce glucose-6-phosphate. Administration of EMS and metformin to STZ diabetic rats resulted in a significant reversal in the activity of hexokinase.

The activity of glucose-6-phosphate dehydrogenase the first regular enzyme of pentose phosphate pathway was found to be decreased in diabetic animals [45] and increased in EMS and Metformin treated animals. The activity was higher in comparison to untreated diabetic animals indicating improvement in glucose utilization by this pathway. This may be attributed to the insulin secretory effect of EMS as glucose-6-phosphate dehydrogenase has been reported to increase the supply of NADPH.

The hepatic gluconeogenic enzymes, glucose-6-phosphatase and fructose-1, 6-bisphosphatase were increased significantly in diabetic rats [46]. The increased activities of two gluconeogenic enzymes from liver may be due to the activation or increased synthesis of the enzymes contributing to the increased glucose production during diabetes, by liver, and EMS and metformin treatment may be primarily modulating and regulating the activities of the two gluconeogenic enzymes, either through regulation by cyclic AMP and any other metabolic activation or inhibition of glycolysis and gluconeogenesis [47].

Administration of EMS and Metformin significantly decreased the activities of gluconeogenic enzymes in diabetic rats. The level of plasma insulin was found to increase significantly in diabetic rats treated with EMS, which may be a consequence for the significant reduction in the level of gluconeogenic enzymes. The reduction in the activities of gluconeogenic enzymes can result in the decreased concentration of glucose in blood.

In conclusion our result indicate that non-glycidic nutrient EMS possess antidiabetic action. The present investigation draws out a sequential metabolic correlation between increased glycolysis and decreased gluconeogenesis, increased hydrogen shuttle reaction and normal glycemia stimulated by succinic acid mono ethyl ester, which may have been the biochemical mechanism through which glucose homeostasis is regulated.

#### ABBREVIATIONS

EMS - Succinic acid monoethyl ester  
 NIDDM - Non insulin dependent diabetes mellitus  
 STZ - Streptozotocin  
 bw - Body weight

#### REFERENCES

1. Cowie CC, Eberhardt MS. Diabetes: Vital Statistics. American Diabetes Association, 1996 Alexandria, VA.
2. Gupta D, Raju J, Prakash JR, Baquer NZ. Changes in the lipid profile, lipogenic and related enzymes in the liver of experimental diabetic rats: effect of insulin and vanadate. *Diab Res Clin Pract* 1999;**46**:1-7.

3. Sochar M, Baquer NZ, Mclean P. Glucose under utilization in diabetes. Comparative studies on the changes in the activities of enzymes of glucose metabolism in rat kidney and liver. *Mol Physiol* 1985;**7**:51-68.
4. Reaven GM. Role of insulin-resistance in human diseases. *Diabetes* 1998;**37**:1597-607.
5. Gorbenko NI, Poltork VV, Gladkikh AI, Ivanova OV. Effect of phensuccinal on pancreatic beta cell in rats with neonatally induced streptozotocin diabetes mellitus. *Bull Exp Biol Med* 2001;**132**:556-9.
6. Alarcon C, Wicksteed B. Succinate is a preferential metabolic stimulus-coupling signal for glucose-induced proinsulin biosynthesis translation. *Diabetes* 2002;**51**:2496.
7. Zawulich WS, Zawulich KC. Biochemical mechanisms involved in monomethyl succinate-induced insulin secretion. *Endocrinol* 1992;**131**:649-54.
8. Juan A, Martinez G, Maria L Penacarrillo V, Valverde I, Bjorkling F, Malaisse WJ. Potentiation of the insulinotropic and hypoglycemic action of gliquidone by succinic acid esters. *European J Pharmacol* 1998;**325**:65-8.
9. Akkan AG, Malaisse WJ. Iterative pulse administration of succinic acid monomethyl ester to streptozotocin diabetic rats. *Diabetes Res* 1993;**23**:55-63.
10. Decio L, Eizirik DL, Welsh N, Niemann A, Velloso LA, Malaisse WJ. Succinic acid monomethyl ester protects rat pancreatic islet secretory potential against interleukin-1 $\beta$  (IL-18) without affecting glutamate decarboxylase expression or nitric oxide production. *FEBS Letters* 1994;**337**:298-302.
11. Decio L, Eizirik DL, Delaney CA, Green MHL, Cunningham JM, Thorpe JR, Pipeleers DS, Hellerstrom C, Green IC. Nitric oxide donors decrease the function and survival of human pancreatic islets. *Molecu Endocrinol* 1996;**118**:71-83.
12. Zang TM, Sener A, Malaisse WJ. Metabolic effect and Rate of succinic acid methyl ester in rat hepatocytes. *Arch Biochem Biophys* 1994;**314**:186-192.
13. Neil MJ. Metformin the merck index, 13th ed. Rahway: Merck & Co. Inc 2001 p. 5966.
14. Frendell MS, Glazer NB, Zhan YE. Combination therapy with pioglitazone plus metformin or sulfonyleurea in patients with type 2 diabetes influence of prior antidiabetic drug regimen. *J Diabetes Complicat* 2003;**17**:211-17.
15. Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes G. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. *Diabetes* 1998;**47**:224-9.
16. Yanardag R, Ozsoy-Sacan O, Bolkent S, Orak H, Karabulut-Bulan O. Protective effects of metformin treatment on the liver injury of streptozotocin-diabetic rats. *Hum Exp Toxicol* 2005;**24**:129-35.
17. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. *Ann Clin Biochem* 1969;**6**:24-7.
18. Drabkin DL, Austin JM. Spectrophotometric constants for common hemoglobin derivatives in human, dog and rabbit blood. *J Biol Chem* 1932;**98**:719-33.
19. Sudhakar Nayak S, Pattabiraman TN. A new colorimetric method for the estimation of glycosylated hemoglobin. *Clin Chem Acta* 1981;**109**:267-74.
20. Bannon P. Effect of pH on the elimination of the labile fraction of glycosylated hemoglobin. *Clin Chem* 1982;**28**:2183.
21. Koida H, Oda T. Pathological occurrence of glucose-6-phosphatase in liver disease. *Clin Chim Acta* 1959;**74**:554-61.
22. Gancedo JM, Gancedo C. Fructose-1, 6-bisphosphatase, phosphofructokinase and glucose-6-phosphate dehydrogenase from fermenting and non-fermenting yeasts. *Arch Microbiol* 1971;**76**:132-38.
23. Fiske CH, Subbarow J. The colorimetric determination of phosphorous. *J Biol Chem* 1925;**66**:375-400.

24. Brandstrup N, Kirk JK, Bruni C. Determination of hexokinase in tissues. *J Gerontol* 1957;**12**:166-71.
25. Ellis HA, Kirkman HN. A colorimetric method for assay of erythrocyte glucose-6-phosphate dehydrogenase. *Proc Soc Exp Biol Med* 1961;**106**:607-9.
26. Morales MA, Jabbagy AJ, Tenenzi HP. Mutation affecting accumulation of glycogen. *Neurospora News Lett* 1973;**20**:24-5.
27. Malaisse WJ. The esters of carboxylic nutrients as insulinotropic tools in non-insulin-dependent diabetes mellitus. *Gen Pharmacol* 1995;**26**:1133-41.
28. Ladriere L, Louchami K, Vinamber C, Kadiata MM, Jijakli H, Villanueva Penacarrillo ML, Valverde I, Malaisse WJ. Insulinotropic action of the monoethyl ester of succinic acid. *Gen Pharmacol* 1998;**31**:377-83.
29. Ladriere L, Malaisse WJ. Nutritional value of succinic acid monoethyl ester in starvation. *Ann Nutr Metab* 1997;**41**:118-25.
30. Latner A. In: Clinical Biochemistry. Saunders, Philadelphia; 1958. p. 48.
31. Eto K, Tsubamoto Y, Terauchi Y, et al. Role of NADH shuttle system in glucose induced activation of mitochondrial metabolism and insulin secretion. *Science* 1999;**283**:981-5.
32. Ishihara H, Wang H, Drewes LR, Wollheim CB. Overexpression of monocarboxylate transporter and lactate dehydrogenase alters insulin secretory responses to pyruvate and lactate in beta cells. *J Clin Invest* 1999;**104**:1621-9.
33. Ainscow EK, Zhao C, Rutter GA. Acute over expression of lactate dehydrogenase-A perturbs beta-cell mitochondrial metabolism and insulin secretion. *Diabetes* 2000;**49**:1149-55.
34. Bailey CJ, Turner RC. Metformin. *N Engl J Med* 1996;**334**:574-9.
35. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. *Diabetes Rev* 1998;**6**:98-131.
36. Cusi K, Consoli A, DeFronzo RA. Metabolic effect of metformin on glucose and lactate metabolism in non-insulin dependent diabetes mellitus. *J Clin Endocrinol Metab* 1996;**81**:4059-67.
37. Christiansen MP, Linfoot PA, Neese RA, Hellerstein M. Metformin effects upon post absorptive intra hepatic carbohydrate fluxes. *Diabetes* 1997;**46**:244A.
38. Stumvoll M, Nurjhan N, Periello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin dependent diabetes mellitus. *N Engl J Med* 1995;**333**:550-4.
39. Alberti KG, MM Press CM, In: Keen H, Jarre J. editors. The Biochemistry and the complications of diabetes. New York: Edward Arnold Publishers; 1982.p. 231-270.
40. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin A1 C in diabetes mellitus. *N Engl J Med* 1976;**295**:417-20.
41. Thomas MC, Macisaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes. *Diabetes Care* 2003;**26**:1164-9.
42. Pari L, Latha M. Antihyperglycaemic effect of Scoparia dulcis Effect on key metabolic enzymes of carbohydrate metabolism in streptozotocin induced diabetes. *Pharmaceu Biol* 2004;**42**:1-7.
43. Garvey WT, Olefsky JM, Marshall S. Insulin receptor down regulation is linked to an insulin-induced post receptor defect in the glucose transport system in rat adipocytes. *J Clin Invest* 1985;**76**:22-30.
44. Dyer DG, Dunn JA, Thorpe SR, Bailie KE. Accumulation of Maillards reaction products in skin collagen in diabetes and aging. *J Clin Invest* 1993;**91**:2463-9.
45. Singh SM, Vats P. Effect of an antidiabetic extract of Catharanthus roseus on enzymic activities in streptozotocin induced diabetic rats. *J Ethnopharmacol* 2001;**76**:269-77.
46. Baquer NZ, Gupta D, Raju J. Regulation of metabolic pathways in liver and kidney during experimental diabetes. Effect of anti-diabetic compounds. *Ind J Clin Biochem* 1998;**13**:63-80.
47. Ashokkumar N, Pari L. Effect of N-benzoyl-D-phenylalanine and metformin on carbohydrate metabolic enzymes in neonatal streptozotocin diabetic rats. *Clin Chim Acta* 2005;**351**:105-113.

---

**Address correspondence to:** Dr. L Pari, Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalai Nagar-608 002, Tamil Nadu, India. Tel: + 914144 238343. Fax: + 914144 238145. E-mail: [paribalaji@gmail.com](mailto:paribalaji@gmail.com)

---